

Hermina – Our Team







1. Company Overview

Introduction to Hermina

Hermina is one of the largest hospital groups in Indonesia with more than 38 years of experience in women and children care and a differentiated business model. Hermina is uniquely positioned to take advantage of low healthcare penetration and universal health coverage roll-out through the Jaminan Kesehatan Nasional ("JKN") scheme in Indonesia.

Unique Business Model

- One of the Largest Private Hospital Groups
 - 46 hospitals and 6,578 beds as of September 30, 2023
 - **General hospital** providing a wide range service offerings, with a strong heritage in women and children care
- 'Doctor Partnership' Model
 - Top specialist doctors own a minority stake at each hospital
 - (i) Helps to attract and retain quality doctors, and (ii) supports growth plan going forward
- Patient Segment Positioning Fast growing middle class and rising affluence
 - Strength in women and children care provides a good entry point for Indonesians of productive age
- Early Mover Advantage in JKN Visits driven by JKN, as well as private pay, insurance, and corporate patients
- Proven Track Record Successfully developing new hospitals and optimizing capacity while maintaining profitability
- Alignment of Interest Doctor Partners + selfowned properties + fully committed founders and credible institutional investors

Key Statistics (FY22)



6.6M +

484K+

Annual Out-Patient Visits

Annual In-Patient Admissions



4,300+

Doctors and Specialists



73K+

Annual Babies Delivered




100%

JKN Participation Across Hospitals



Full Service Offering of General Hospitals

Hermina hospitals are a network of general hospitals with a significant strength and wide offering in women and children care



- 8 Type B general hospitals with fully advanced center of excellence & subspecialist care
- 38 Type C full service general hospitals with several sub-specialist care

Hermina Hospital Facility-









Radiology



Accident & Emergency

Pharmacv

Outpatient Clinics & Homecare

Inpatient rooms

Laboratory

Service Offerings

No.1 in Women and Children Care2...

Market Leader in Number of Sub-specialty Service Offerings²

Obstetrics & Gynaecology



Specializes in women's health including Oncology and Urogynaecology

Service of Excellence

- Feto-maternal care
- Infertility

Pediatrics



Children's health including tertiary care such as Gastroenterology and Thalassemia

Service of Excellence

- Perinatology
- Neonatal Intensive Care Units (NICU)
- Pediatric Intensive Care Units (PICU)

Internal Medicine



Haemodialysis, CAPD, Gastrointestinal Endoscopy, Geriatrics Clinic, Oncology -Chemotherapy

Diagnostics / Imaging



General X-ray & Ultrasound, Mammography, BMD, MRI, CT Scan, C-Arm, ENT

Surgical Procedures



Orthopaedics and Traumatology, Oncology - Chemotherapy, Neuro surgery, Plastic surgery, Vascular surgery, Digestive (Laparoscopy) and Urology (ESWL & TURP), Phacoemulsification

Endoscopy, Pathology-Clinic

Cardiovascular



A variety of health screening and treatment such as Cath Lab

Medical Rehabilitation



Service of Excellence Growth and Development Center which includes Children Bobath to treat Cerebral Palsy and care for Neuromuscular diseases, and Adult Bobath to treat Stroke and Brain Injury

Dental Specialists



Service of Excellence Orthodontics. Conservative Dentistry, Pediatric Dentistry, Prosthodontics, Periodontics and Oral Surgery

Other Specialties



Ophthalmology Acupuncture Neurology Psychiatry Pathology-AnatomicPsychology Anaesthesiology Radiology


Pulmonology Dermatology & Venereology Otorhinolaryngology (ENT)



^{1.} As of September 30, 2023

^{2.} Based on Frost & Sullivan's analysis that within the top private multi-specialty hospital chains, Hermina has the broadest offerings in women & children segment

Corporate History



Our Nationwide Hospital Network

Our Nationwide Hospital Network

Type B Hospitals



Jatinegara



Kemayoran



Bekasi



Depok



Daan Mogot



Bogor



Grand Wisata



Pasteur

Type C Hospitals

- Pandanaran
- Sukabumi
- Tangerang
- Arcamanik
- Galaxy
- Palembang
- Ciputat
- Mekarsari
- Serpong

- Banyumanik
- Tangkubanprahu Solo
 - Ciruas
 - Yoqya
 - Bitung
 - Makassar
 - Balikpapan
 - Medan
 - Podomoro
 - Purwokerto

- Samarinda
- Jakabaring
- Padang
- Lampung
- Pekalongan
- Pekanbaru
- Kendari
- Wonogiri
- Karawang
- Manado

- Periuk **Tangerang**
- Salatiga
- Ciledug
- Cibitung
- Cilegon
- Soreang
- Tasikmalaya
- Ciawi

Total Hospitals

46 Hospitals¹









2. Financial Update

Robust Performance Reaffirms Management Execution Ability










Increasing PATMI as % of PAT

^{1.} EBITDA is calculated by operating income + depreciation and amortization + adjustment for non-operating items (loss on disposal of fixed asset, gain on sale of fixed asset, and other income (expense)) and adjustment for non-cash items (allowance for impairment losses and post-employment benefit expense).

Prudent Working Capital Management Despite Serving BPJS






Trade Receivable Amount

Net Working Capital

(IDR billions)




^{1.} Trade receivable days are calculated based on the average of beginning and ending balance of trade receivables over the period of last 12 months (LTM) divided by LTM Sales.

^{2.} Calculated based on the average of beginning and ending balance of LTM period divided by LTM COGS.

^{3.} Calculated based on the average of beginning and ending balance of LTM period divided by LTM COGS. The other account payable to related parties is included

Stabilization in Traffic Mix due to Improving Macro

Inpatient Days



- Bed Occupancy Ratio (BOR) was 60% in 9M22 and 71% in 9M23
- Average Length of Stay (ALOS) was 2.8 days in 9M22 and 2.8 days in 9M23

Outpatient Visit



Inpatient Days by Payor Type



Outpatient Visits by Payor Type



Continued Transformation Drives Margin Improvement

| (IDR billions) | 3Q23 | 9M23 |
|---|---------|---------|
| Revenue | 1,538.5 | 4,229.9 |
| EBIT | 270.3 | 639.3 |
| % Margin | 17.6% | 15.1% |
| + Depreciation and Amortization (D&A) | 188.7 | 505.3 |
| Adjustment for back non-cash items ¹ | | |
| + Post-employment benefits | 7.6 | 22.7 |
| + Allowance for impairment losses | 2.5 | 2.6 |
| Adjustment for non-operational income / (expense) | | |
| + Loss on disposal of fixed asset | 0.0 | 0.1 |
| - Other income / (expense) ² | 3.8 | 5.0 |
| EBITDA (EBIT + D&A + Adjustments) | 465.4 | 1,164.9 |
| % Margin | 30.2% | 27.5% |

^{2.} Other income and expenses include items that are non-operational in nature such as sponsorship income, seminar income, patient overpayment, and other miscellaneous income and expenses. Other income and expenses exclude the minority shares subscription income (IDR 4.9 bn in Sept 30, 2023).




^{1.} Methodology is consistent with the EBITDA calculation methodology of the peer group of Siloam and Mitra Keluarga.

Consistent Low Cost of Debt Despite Higher Interest Rate Climate



(IDR billions, x)



Robust Credit Profile

Credit Rating AA Reaffirmed by Rating Agency


- In May 2022, PEFINDO has upgraded HEAL's rating to AA from previously AA- for the Company and its public bonds with stable outlook.
- The rating is supported by HEAL's very strong market position in the hospital industry with proven track record, very strong financial profile, and stable profit margin.
- In Jul 2022, HEAL has successfully issued new public bonds, which comprises of:
 - 3-year bond with interest rate of 6.25% p.a.
 - 5-year bond with interest rate of 6.75% p.a.
- In May 2023, PEFINDO has reaffirmed AA rating.
- HEAL has paid off IDR 425.5 bn bond in Sep 2023.


Loans from Top Reputable Banks

- Key lenders include **Bank Mandiri** and **BCA**.
- All Debt are Denominated in Local Currency



Capital Expenditure is Expected to Normalize to IDR1-1.2 Tn in 2023-2024










3. Other Development

Hospital Under Development

Hermina Aceh











4. Appendix

Investor Relations Contact and Coverage

Investor Relations Contact: ir@herminahospitals.com

Analyst Coverage

| Brokerage Company | Analyst | Share Price Target (IDR) ¹ | Rating |
|-------------------------------|------------------------------------|---------------------------------------|------------|
| Bahana Sekuritas | Robert Sebastian | 1,760 | Buy |
| BCA Sekuritas | Mohammad Fakhrul Arifin | 1,920 | Buy |
| BNI Sekuritas | Aurellia Setiabudi | 1,650 | Buy |
| BRI Danareksa | Ismail Fakhri | 1,600 | Buy |
| CGS CIMB | Ryan Winipta | 1,800 | Add |
| Citi | Lakshmi Rowter | 1,800 | Buy |
| CLSA | Chelene Indriani | 1,800 | Buy |
| Credit Suisse | Steven Ho | 1,830 | Outperform |
| DBS | Cheria Christi Widjaja | 1,745 | Buy |
| Henan Putihrai Sekuritas | Jono Syafei | 1,450 | Buy |
| Korea Investment | Filia Gladwyn | 1,500 | Hold |
| Macquarie | Ari Jahja | 1,590 | Outperform |
| Mandiri Sekuritas | Inggrid Gondoprastowo | 1,620 | Buy |
| Mirae Asset Sekuritas | Rut Yesika Simak, Emma Fauni | 1,700 | Buy |
| MNC Sekuritas | Muhammad Rudy Setiawan | 1,730 | Buy |
| Panin Sekuritas | Andhika Audrey | 1.600 | Buy |
| Phillip Sekuritas | Helen | 1,300 | Buy |
| Pilarmas Investindo Sekuritas | Nico Demus | 1,600 | Hold |
| RHB | Vanessa Karmajaya | 1,700 | Buy |
| Samuel Sekuritas | Jonathan Guyadi, Brandon Boedhiman | 1,650 | Buy |
| Sinarmas Sekuritas | Michael Filbery | 1,700 | Buy |
| Sucor Sekuritas | Jennifer Widjaja | 1,585 | Buy |
| Trimegah Sekuritas | Heribertus Ariando | 1,440 | Buy |
| Valbury Sekuritas | Alfiansyah, Devi Harjoto | 1,225 | Buy |
| Verdhana Sekuritas | Jody Wijaya, Sandy Ham | 1,980 | Buy |
| Maybank Kim Eng | Adi Wicaksono | TBC | TBC |
| Indo Premier Sekuritas | Laura Oei | TBC | TBC |

^{1.} Adjusted with the stock split (1:5) which was effective on 30 July 2021





PT Medikaloka Hermina Tbk

www.herminahospitals.com